Fiche publication
Date publication
septembre 2022
Journal
Blood
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
,
Pr FEUGIER Pierre
Tous les auteurs :
Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, Gros FX, Choquet S, Bories P, Feugier P, Casasnovas O, Bay JO, Mohty M, Joris M, Gastinne T, Sesques P, Tudesq JJ, Vercellino L, Morschhauser F, Gat E, Broussais F, Houot R, Thieblemont C
Lien Pubmed
Résumé
Anti-CD19 CAR T-cells represent a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant number of patients experiences failure. Among 550 patients registered in the French registry DESCAR-T, 238 (43.3%) experienced progression/relapse, with a median follow-up of 7.9 months. At registration, 57.0% of patients presented an age adjusted International Prognostic Index of 2-3, 18.9% had ECOG performance status ≥2, 57.1% received >3 lines of treatment prior to receiving CAR T-cells, and 87.8% received bridging therapy. At infusion, 66% of patients presented progressive disease and 38.9% high lactate dehydrogenase (LDH). Failure after CAR T-cells occurred after a median of 2.7 months (range, 0.2-21.5). Fifty-four (22.7%) patients presented very early failure (day [D] 0-D30); 102 (42.9%) had early failure (D31-D90), and 82 (34.5%) had late (>D90) failure. After failure, 154 (64%) patients received salvage treatment: 38.3% had lenalidomide, 7.1% bispecific antibodies, 21.4% targeted treatment, 11% radiotherapy, and 20% immuno-chemotherapy with various regimens. Median progression-free survival was 2.8 months, and median overall survival (OS) was 5.2 months. Median OS for patients failing during D0-D30 versus after D30 was 1.7 vs 3.0 months respectively (p=0.0001). Overall, 47.9% of patients were alive at 6 months, but only 18.9% were alive after very early failure. In multivariate analysis, predictors of OS were high LDH at infusion, time to CAR-T failure
Référence
Blood. 2022 09 19;:
